STAT+: Novo Nordisk strikes deal with U.S. startup to develop oral obesity, diabetes drugs
STAT [Unofficial]
February 25, 2026
Novo Nordisk announced it had signed a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral obesity and diabetes drugs.
Discussion in the ATmosphere